Milestone 1 Structural information of PCSK9 variants
Milestone 2 Potential new PCSK9-variants involved in hypercholesterolemia
Milestone 3 Structural description of the interaction between PCSK9 and selected interactors
Objective 1
Characterization of selected PCSK9 variantsng is awesome
Objective 2
Structural chacterization of relevant details of PCSK9/cIAP1 interaction
Milestone 4 Structural information about PCSK9/BIR3 complex
Milestone 6 Potential molecules inhibiting PCSK9-involving complex formation
Milestone 5 Structural description of the interaction between CT (PCSK9) and LBD (LDLr) domains
Milestone 6 Potential molecules inhibiting PCSK9-involving complex formation